Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

200 Technology Square
Cambridge, MA

Tel: 617-714-6500

Visit website

Email Us

Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.

Every Role Matters, Enabling Transformative Mission

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.

Read Keke’s Story

Take your moment with benefits

We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.

Learn More

NEWS

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).

FDA

FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision

The disagreement between Moderna and the FDA has reached a resolution just eight days after the biotech received a Refusal-to-File letter in response to its application for mRNA-1010. Moderna will now seek approval of the vaccine based on age.

February 18, 2026

3 min read

Heather McKenzie

Legal

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

February 18, 2026

2 min read

Tristan Manalac

Podcast

Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have had a hand in; Compass Pathways posts new late-stage data on its psilocybin-based depression drug; CDC is once again leaderless.

February 18, 2026

1 min read

Heather McKenzie

FDA

Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA Medicines. Meanwhile, streamlined communications with regulators in other countries pave the way for rapid uptake of novel modalities.

February 17, 2026

5 min read

Heather McKenzie

A bottle of a vaccine on a reflective surface with the illuminated red outline of the world map in red - 3D render

Vaccines

Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology.

February 16, 2026

3 min read

Annalee Armstrong

Businessman on a crossroad. Man choosing career. Searching of right path. Decision and brainstorming concept. Flat vector illustration.

Earnings

Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation

Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.

February 13, 2026

5 min read

Annalee Armstrong

FDA

FDA’s Prasad Weathers Personal Controversy, Internal Strife Amid Moderna Imbroglio

Vinay Prasad, the FDA’s Center for Biologics Evaluation and Research head, is accused of interpersonal impropriety as pushback builds against his decision to reject Moderna’s influenza vaccine candidate.

February 12, 2026

2 min read

Dan Samorodnitsky

Contemporary artwork. Businessman jumping over bear trap with briefcase and documents. Concept of business risk, hidden financial dangers, legal pitfalls, investment fraud and consumer protection.

Vaccines

Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans

Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.

February 12, 2026

4 min read

Dan Samorodnitsky

Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace

Regulatory

HHS Backs Prasad Amid Moderna Flu Shot Blowback

An unnamed FDA official also told reporters that it would be good for Moderna to “show some humility” and admit that it didn’t follow the regulator’s recommendations in testing its mRNA flu vaccine.

February 12, 2026

2 min read

Tristan Manalac

JOBS